Kalshi Launches Prediction Markets for Biopharma Clinical Trials and FDA Approvals

Kalshi, a prediction market exchange, announced it will begin testing markets on clinical trial outcomes and FDA approval decisions, initially focusing on late-stage Phase 3 trials conducted by established biopharma companies. The company aims to provide a new tool for investors and improve drug development decisions while implementing safeguards to prevent insider trading and trial manipulation. Experts express concerns about potential risks to trial integrity and the actual usefulness of predictions, especially in early-stage research, but Kalshi aims to expand into more uncertain areas in the future.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل